Eton Pharmaceuticals, Inc. (NASDAQ:ETON) is reporting second quarter earnings results on Wednesday 12th August 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.26 per share from $ 0.29 million in revenue.
For the full year, analysts predict revenues of $ 5.60 million, while looking forward to loss of $ 1.23 per share.
Previous Quarter Performance
Eton Pharmaceuticals, Inc. revealed loss for the first quarter of $ 0.50 per share, from the revenue of $ 0.10 million. The quarterly earnings down 22.38 percent while revenues compared with the same quarter last year.
According to street consensus, ETON was expected to report 1Q20 loss of $ 0.22 per share from revenue of $ 1.51 million. The bottom line results missed street analysts by $ 0.28 or 127.27 percent, at the same time, top line results fell short of analysts by $ 1.41 million or 93.38 percent.
Stock Performance
According to the previous trading day, closing price of ETON was $ 6.85, representing a 174.00 % increase from the 52 week low of $ 2.50 and a 21.62 % decrease over the 52 week high of $ 8.74.
The company has a market capital of $ 143.55 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Eton Pharmaceuticals, Inc. will be hosting a conference call at 4:30 PM eastern time on 12th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.etonpharma.com
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products. It primarily focuses on liquid products, including injectable, oral liquid, and ophthalmic products. The company develops EM-100, an ophthalmic product for the treatment of allergic conjunctivitis; ET-202 and ET-203, which are injectable product candidates for use in the hospital setting; ET-103, an oral liquid product candidate for hypothyroidism; ET-101, ET-102, and ET-104, which are oral liquid product candidates for neurological indications; and CT-100, a synthetic corticotropin therapeutic candidate for rheumatoid arthritis.
